Ghasemi Faezeh, Ghayour-Mobarhan Majid, Gouklani Hamed, Meshkat Zahra
Dept. of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Dept. of Medical Biotechnology, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Iran J Pathol. 2018 Spring;13(2):113-124. Epub 2018 Jul 17.
Hepatitis C virus (HCV) is responsible for a vast majority of liver failure cases. HCV is a kind of blood disease estimated to chronically infect 3% of the worlds population, causing significant morbidity and mortality. Therefore, a complete knowledge of humoral responses against HCV, resulting antibodies, and virus-receptor and virus-antibody interactions, are essential to design a vaccine. HCV epitopes or full sequence of HCV proteins can induce HCV specific immune responses. In fact, structural proteins are usually the main target of humoral responses and non-structural proteins are usually the main target of cellular responses. Hence, various vaccines based on distinct antigenic combinations are developed to prevent HCV infection and the current study tried to summarize them.
丙型肝炎病毒（HCV）是绝大多数肝衰竭病例的病因。HCV是一种血液疾病，估计全球有3%的人口受到慢性感染，导致严重的发病率和死亡率。因此，全面了解针对HCV的体液免疫反应、产生的抗体以及病毒-受体和病毒-抗体相互作用，对于设计疫苗至关重要。HCV表位或HCV蛋白的完整序列可诱导HCV特异性免疫反应。事实上，结构蛋白通常是体液免疫反应的主要靶点，而非结构蛋白通常是细胞免疫反应的主要靶点。因此，人们开发了基于不同抗原组合的各种疫苗来预防HCV感染，本研究试图对这些疫苗进行总结。
